MX1 and systemic lupus erythematosus: Our data on MX1 and ISGs are in line with the literature where splenocytes from lupus-prone mice treated with tofacitinib (10 mg/kg daily) showed also decreased expression of MX1 and ISGs in comparison to untreated control animals [40].